June 6, 2017August 24, 2022
University of Michigan Researchers Identify 16 New Genetic Markers That Shed Light on Psoriasis
News
University of Michigan researchers have shed more light on the genetic landscape behind the intricate mechanisms of psoriasis. The 16 ... Read more
June 1, 2017
OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream in Germany
News
One World Cannabis Pharmaceutical Research (OWCP) and mediq Innovation Experts have partnered to introduce OWCP’s cannabinoid-based topical psoriasis cream in Germany. ... Read more
May 30, 2017May 30, 2017
FDA Approves BLA Filing for Sun Pharma’s Lead Candidate Therapy Tildrakizumab to Treat Plaque Psoriasis
News
The U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for Sun Pharmaceutical’s lead investigational drug tildrakizumab ... Read more
May 25, 2017May 25, 2017
Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis
News
Janssen announced two new Phase 3 clinical trials for psoriasis for its investigational drug guselkumab. The company intends to explore ... Read more
May 23, 2017
Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13, Clinical Trial Suggests
News
Patients taking Remicade (infliximab) can safely switch to treatment with biosimilar CT-P13, sold as Pfizer’s Inflectra and Celltrion Healthcare’s Remsima, according to ... Read more
May 16, 2017May 16, 2017
Cannabinoids Have Potential to Treat Skin Conditions Like Psoriasis, Review Shows
News
Compounds extracted from the cannabis plant (cannabinoids) have therapeutic proprieties that could be used to treat several skin conditions, including psoriasis, ... Read more
May 11, 2017
Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target
News
An already started Phase 2b clinical trial of Prurisol as a treatment for moderate-to-severe chronic plaque psoriasis has recruited more than 70 ... Read more
May 9, 2017
Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease
News
Pfizer’s rheumatoid arthritis drug Xeljanz (tofacitinib) was effective against nail psoriasis in patients with plaque disease, according to data from ... Read more
May 4, 2017May 4, 2017
FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients
News
The U.S. Food and Drug Administration (FDA) will review Pfizer’s medication Xeljanz (tofacitinib citrate) 5 mg twice daily, to treat adults with ... Read more
May 2, 2017
Cimzia and Cosentyx Approved to Treat Active Psoriatic Arthritis in England and Wales
News
The U.K.’s National Institute for Health and Care Excellence (NICE) has approved the use of Cimzia (certolizumab pegol) and Cosentyx (secukinumab), ... Read more
April 27, 2017April 27, 2017
Valeant Prices Plaque Psoriasis Treatment, Siliq, at $3,500 a Month
News
Siliq (brodalumab) injection, recently approved to treat adults with severe plaque psoriasis, will be available in the U.S. at a ... Read more
April 20, 2017April 20, 2017
XTRAC Light Therapy Effectively Treats Psoriasis Lesions Without the Serious Side Effects of Rival Therapies, Says Strata
News
XTRAC targeted-light therapy safely treats skin lesions in psoriasis patients without the serious side effects linked to Humira and other conventional psoriasis drugs, ... Read more

July 18, 2016July 18, 2016

First Combination Foam Spray for Psoriasis, Enstilar, Now Available in UK

News

Adults with psoriasis who live in the United Kingdom will now have a new treatment option available to manage the disease. LEO Pharma’s Enstilar is the first plaque psoriasis treatment available ... Read more

July 18, 2016July 18, 2016

Pro-inflammatory Immune Cell Receptor May Be Key to Start of Psoriasis

News

Researchers in Spain recently identified a receptor of the immune system that appears to play a pivotal role in the development of psoriasis, highlighting a possible new therapeutic avenue for the disease. The study, “CD69 ... Read more

July 14, 2016

FDA Panel Recommends Amgen’s ABP 501 as Biosimilar to Humira

News

The Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) recommends licensing Amgen’s ABP 501 as a biosimilar product to AbbVie’s FDA-approved Humira (adalimumab) for the treatment of patients with ... Read more

July 13, 2016

August, Psoriasis Awareness Month, to Bring Weekly ‘Challenges’ and Health Tips

News

This August, Psoriasis Awareness Month, the National Psoriasis Foundation (NPF) will launch a campaign with the twin goals of helping psoriasis patients to take better care of their health and of raising awareness about the 7.5 million ... Read more

July 7, 2016July 7, 2016

TNF Inhibitors Seen to Lower Cardiovascular Disease Risk in Psoriasis Patients

News

TNF inhibitors are commonly used to treat psoriasis and psoriatic arthritis patients, who are also at high risk of cardiovascular disease. Researchers investigated whether these drugs play a role in elevating that ... Read more

July 1, 2016July 1, 2016

Psoriasis Patients at Risk of Metabolic Syndrome and Cardiovascular Changes, Study from India Finds

News

A recent study evaluated the prevalence of metabolic syndrome and subclinical atherosclerosis in an Indian population with chronic plaque psoriasis, and found a higher prevalence in psoriasis patients when compared to controls. ... Read more

June 30, 2016July 1, 2016

Global Psoriasis Survey Shows 85% of US Patients Faced Discrimination

News

Results from the largest global survey on moderate-to-severe psoriasis patients, called Clear About Psoriasis Survey, were released recently by Novartis Pharmacueticals. Comprising 25 groups worldwide, it was the largest collaboration led by ... Read more

June 28, 2016

Role of Interleukin-33 in Skin Psoriasis, Inflammatory Diseases Studied by Researchers

News

Researchers investigated the role of a molecule, interleukin (IL)-33, in a skin psoriasis mouse model to further understand the role of this cytokine in inflammatory diseases. The findings suggest the molecule ... Read more

June 24, 2016

Review of Literature About Psoriasis, Sleep Disturbance Inconclusive

News

Researchers conducted a review of literature focused on psoriasis and sleep disturbances. The findings, although inconclusive largely because of scant data concerning prevalence and the nature of sleep disturbances, led researchers to ... Read more

June 22, 2016

Psoriasis Patients Show Higher Presence of Metabolic Syndrome, Study Says

News

Researchers at the Medical University of Lodz accessed the prevalence of metabolic syndrome characteristics in patients with psoriasis, and how such abnormalities affect the disease activity. The findings suggest higher ... Read more

University of Michigan Researchers Identify 16 New Genetic Markers That Shed Light on Psoriasis

OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream in Germany

FDA Approves BLA Filing for Sun Pharma’s Lead Candidate Therapy Tildrakizumab to Treat Plaque Psoriasis

Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis

Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13, Clinical Trial Suggests

Cannabinoids Have Potential to Treat Skin Conditions Like Psoriasis, Review Shows

Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target

Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease

FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients

Cimzia and Cosentyx Approved to Treat Active Psoriatic Arthritis in England and Wales

Valeant Prices Plaque Psoriasis Treatment, Siliq, at $3,500 a Month

XTRAC Light Therapy Effectively Treats Psoriasis Lesions Without the Serious Side Effects of Rival Therapies, Says Strata